2025
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Cummings J, Atri A, Feldman H, Hansson O, Sano M, Knop F, Johannsen P, León T, Scheltens P. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer's Research & Therapy 2025, 17: 14. PMID: 39780249, PMCID: PMC11708093, DOI: 10.1186/s13195-024-01666-7.Peer-Reviewed Original ResearchConceptsSymptomatic ADAlzheimer's diseaseDouble-blindGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled phase 3 trialOnce-daily oral semaglutideClinical Dementia RatingMild cognitive impairmentAD-related processesAD biomarkersSafety of semaglutideDose-escalation regimenPhase 3 studyBaseline to weekEffect of semaglutidePhase 3 trialCognitive impairmentPathophysiology of Alzheimer's diseasePotential disease-modifying effectsDementia RatingSymptomatic Alzheimer's diseaseTreatment of type 2 diabetesPlacebo-controlledType 2 diabetesDisease-modifying potential
2024
Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease
van der Flier W, Scheltens P, Feldman H, Hansson O, Sano M, Bardtrum L, Johannsen P, Jeppesen R, Hansen C, Leon T, Cummings J. Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e088793. PMCID: PMC11713752, DOI: 10.1002/alz.088793.Peer-Reviewed Original ResearchMini-Mental State Examination scoreBaseline dataCognitive scoresClinical Dementia Rating-SumAlzheimer's diseaseApolipoprotein E4 carrier statusClinical Dementia Rating-Sum of Boxes scoresInclusion of participantsMild cognitive impairmentScreening failure rateProportion of individualsMild dementiaGeographic regionsType 2 diabetesBox scoresAD medicationsClinical characteristicsInclusion criteriaCarrier statusNorth AmericaExamination scoresClinical trial populationsPatient characteristicsCognitive impairmentSmall vessel pathology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply